Induction of immune tolerance in haemophilia A inhibitor patients by the 'Bonn Protocol': Predictive parameter for therapy duration and outcome

Vox Sanguinis

Volumn 77, Issue SUPPL. 1, 1999, Pages 49-54

  Oldenburg, J ^a,b,c   Schwaab, R ^a   Brackmann, H H ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 INHIBITOR;

ANTIBODY TITER; CATHETER INFECTION; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFERENCE PAPER; FOLLOW UP; GENETIC DISORDER; HEMOPHILIA A; HUMAN; IMMUNOLOGICAL TOLERANCE; INTRAVENOUS CATHETER; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0032883366     PISSN: 00429007     EISSN: None     Source Type: Journal    
DOI: 10.1159/000056717     Document Type: Conference Paper

References (13)

1. Scharrer I, Neutzling O: Incidence of inhibitors in haemophiliacs. A review of the literature. Blood Coag Fibrinol 1993;4:753-758.
2. Brackmann HH, Gormsen J: Massive factor VIII infusion in a haemophiliac with factor VIII inhibitor, high response. Lancet 1977;2: 933.
3. Brackmann HH, Oldenburg J, Schwaab R: Immune tolerance for the treatment of factor VIII inhibitors - Twenty Years 'Bonn Protocol'. Vox Sang 1996,70(suppl 1):30-35.
4. van Leewen EF, Mauser-Bunschoten EP, van Dijken PJ, Kok AJ, Sjamsedin-Visset EJM, Sixma JJ: Disappearance factor VIII: C antibodies in patients with haemophilia A upon frequent administration of factor VIII in intermediate or low dose. Br J Haematol 1986;64: 291-297.
5. Scheibel E, Ingerslev J, Dalsgaard-Nielsen J, Stenberg S, Knudson JB, and the Danish study group: Continuous high-dose factor VIII for the induction of immune tolerance in haemophilia A patients with high responder state: A description of eleven patients treated. Thromb Haemost 1987;58:1049-1052.
6. Ewing N, Sanders NL, Dietrich SL, Kasper CK: Induction of immune tolerance to factor VII in hemophiliacs. JAMA 1988;259:65-68.
7. Mariani G, Ghirardini A, Bellocco R: Immune tolerance in hemophilia - Principal results from the international registry. Report of the factor VIII and IX subcommittee. Thromb Haemost 1994;72:155-158.
8. Kasper CK, Aledort LM, Counts RB, Edson JR, Frantatoni J, Green D, Hampton JW, Hilgardner MW, Lazerson J, Levine PH, McMillan CW, Pool JG, Shapiro SS, Shulman NR, von Eys J: A more uniform measurement of factor VIII inhibitors. Thrombos Diathes Haemorrh 1997;34:869-872.
9. Aledort LM, Cohen M, Hilgartner MW, Lipton R: Treatment of hemophiliacs with Inhibitors: Cost and Effect on Blood Resources. Progr Clin Biol Res 1984;150:353-365.
10. Schwaab R, Brackmann HH, Meyer C, Seehafer J, Kirchgesser M, Haack A, Olek K, Tuddenham EGD, Oldenburg J, Haemophilia A: Mutation type determines risk of inhibitor formation. Thromb Haemost 1995;74:1402-1406.
11. Fijnvandraat K, Turenhout EAM, van den Brink EN, ten Cate JW, van Mourik JA, Peters M, Voorberg J: The missense mutation Arg593 → Cys is related to antibody formation in a patient with mild hemophilia A. Blood 1997;89:4371-4377.
12. Gilles JG, Desqueper B, Lenk H, Vermylen J, Saint-Remy JM: Neutralizing antiidiotypic antibodies to FVIII inhibitors after desensitization in patients with hemophilia A. J Clin Invest 1996;97:1382-1388.
13. Nilsson IM, Berntorp E, Zetterval O: Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide and factor VIII. N Engl J Med 1988;318:947-950.